A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

Trial Profile

A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Masitinib (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 15 Jun 2017 This trial has been suspended in Germany.
    • 20 Apr 2017 Primary endpoint has been changed from Multiple Sclerosis Functional Composite (MSFC) to EDSS.
    • 20 Apr 2017 Planned End Date changed from 1 Dec 2015 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top